The global HERG Screening Market, valued at USD 8.23 billion in 2025, is projected to grow from USD 8.97 billion in 2026 to USD 17.78 billion by 2034, registering a CAGR of 8.94% during the forecast period (2026–2034). The increasing emphasis on cardiac safety assessment in drug discovery and development, coupled with rising incidences of cardiovascular diseases worldwide, is driving substantial demand for HERG screening technologies across pharmaceutical and biotechnology industries.
HERG (Human Ether-à-go-go-Related Gene) screening has become an indispensable component of preclinical drug development, enabling researchers to evaluate potential cardiotoxicity risks before advancing compounds into clinical trials. Regulatory agencies increasingly require HERG screening data as part of investigational new drug submissions, reinforcing the market’s strategic importance within the global life sciences ecosystem.
Market Dynamics & Core Insights
The HERG screening market continues to gain momentum as pharmaceutical companies prioritize cardiac safety profiling during the early stages of drug development. HERG potassium channels play a critical role in regulating cardiac repolarization, and disruptions to these channels can result in prolonged QT intervals, potentially leading to life-threatening arrhythmias such as Torsades de Pointes (TdP).
Rising Burden of Cardiovascular Diseases Driving Demand
The growing prevalence of cardiovascular disorders remains one of the most significant catalysts for market growth. Heart disease continues to be the leading cause of mortality globally, creating an urgent need for safer therapeutic compounds and robust cardiac safety testing platforms.
Increasing rates of hypertension, diabetes, hypercholesterolemia, and sedentary lifestyles are contributing to the surge in cardiovascular disease cases worldwide. As pharmaceutical companies intensify research efforts to develop innovative cardiovascular therapies, the adoption of HERG screening assays is expected to expand significantly.
Regulatory Compliance Strengthening Market Adoption
Global regulatory frameworks increasingly mandate comprehensive cardiac safety assessments before clinical development. HERG screening has emerged as a key requirement for evaluating drug-induced QT prolongation risks, making it an essential component of preclinical testing strategies.
Advanced technologies such as automated patch-clamp assays, fluorescence polarization assays, HERG radioligand binding assays, and microelectrode arrays are enhancing testing efficiency, reproducibility, and throughput, further supporting market growth.
Untapped Emerging Markets Present Significant Opportunities
Emerging economies including China, India, Brazil, Russia, and South Africa represent substantial growth opportunities for market participants. The increasing prevalence of ischemic heart disease, stroke, and other cardiovascular conditions across these regions is fueling demand for innovative drug discovery solutions and cardiac safety testing platforms.
Growing investments in pharmaceutical research infrastructure, expanding biotechnology sectors, and increasing outsourcing activities are expected to accelerate HERG screening adoption in these high-growth markets.
Market Challenge: High Cost of HERG Screening Products
Despite strong growth prospects, the market faces challenges associated with the high cost of screening reagents, assays, and advanced testing platforms. Premium membrane preparations, recombinant cell lines, and specialized electrophysiology systems can significantly increase research expenditures, potentially limiting adoption among smaller research organizations and emerging biotechnology firms.
Segment Highlights
By Type
The Gene KCNH2 segment dominates the market and is anticipated to maintain strong growth throughout the forecast period. KCNH2 is responsible for encoding potassium ion channels essential for electrical signal generation and transmission within the heart. Mutations in the KCNH2 gene have been strongly associated with cardiac arrhythmias and Long QT Syndrome, reinforcing the importance of HERG-focused safety screening.
By Ion Channel
The Voltage-Gated Ion Channel segment represents the largest market share. These channels are fundamental to the functioning of cardiac, neuronal, and skeletal muscle cells and have become major therapeutic targets for various diseases, including epilepsy, neuropathic pain, and cardiovascular disorders.
By Application
The Antiarrhythmic segment remains the leading application area. HERG screening is extensively utilized during the development and safety assessment of antiarrhythmic medications to minimize cardiotoxicity risks and improve patient outcomes.
Regional Analysis
North America Leads Global Market Revenue
North America remains the dominant regional market and is projected to continue leading revenue generation throughout the forecast period. The region benefits from a strong pharmaceutical industry presence, advanced research infrastructure, substantial healthcare expenditure, and stringent regulatory requirements governing drug safety assessments.
The United States, in particular, continues to witness significant investments in cardiovascular drug development and preclinical testing technologies, reinforcing regional market leadership.
Europe Emerges as the Fastest-Growing Region
Europe is expected to register the fastest growth rate during the forecast period. Growing investments in biotechnology research, increasing pharmaceutical innovation, and rising demand for advanced safety screening technologies are contributing to market expansion across major European countries, including Germany, France, the United Kingdom, Italy, and Spain.
Key Market Players
- Abcam PLC A leading provider of life science research tools and reagents, Abcam continues to support drug discovery and ion channel research through its extensive portfolio of antibodies and assay solutions.
- AVIVA Biosciences The company focuses on delivering innovative biological products and screening solutions that facilitate advanced pharmacological and toxicological studies.
- ABR-Affinity BioReagents, Inc. ABR-Affinity BioReagents provides specialized reagents and research products that support HERG screening and broader biomedical research initiatives.
- AstraZeneca plc AstraZeneca remains a major contributor to cardiovascular drug development and actively utilizes advanced cardiac safety assessment methodologies within its research pipeline.
- Aurora Biomed Inc. Aurora Biomed develops high-throughput screening technologies and automation solutions that improve efficiency in pharmaceutical testing and discovery workflows.
- Aureus Sciences The company specializes in bioinformatics and predictive toxicology solutions that assist researchers in evaluating compound safety profiles.
- B’SYS GmbH B’SYS supports pharmaceutical research through specialized screening and analytical technologies designed for ion channel investigations.
- Caliper, A PerkinElmer Company Caliper has played a significant role in advancing high-throughput screening technologies that enhance drug discovery productivity and cardiac safety assessments.
- Cambridge Bioscience Ltd Cambridge Bioscience supplies advanced laboratory tools and research technologies supporting preclinical safety and efficacy studies.
- Cellular Dynamics International The company provides stem cell-derived cellular models that are increasingly utilized in cardiac safety testing and predictive toxicology applications.
- ChanTest Corporation ChanTest is recognized for its expertise in ion channel screening and electrophysiology services, supporting pharmaceutical companies worldwide.
- Charles River Laboratories Inc. Charles River continues to expand its preclinical research capabilities, including strategic collaborations that strengthen pathology analytics and drug safety evaluation services.
- ChemAxon ChemAxon delivers computational chemistry and predictive modeling solutions that support drug discovery and toxicity assessment initiatives.
- Molecular Devices LLC Molecular Devices provides advanced instrumentation and analytical platforms that enable efficient high-content screening and electrophysiological testing.
- Eurofins-Cerep SA Eurofins-Cerep offers comprehensive pharmacology and safety screening services, including specialized HERG assays utilized throughout drug development programs.
Recent Industry Development
In March 2020, Charles River Laboratories entered into a strategic alliance with Deciphex to co-develop deep learning-enabled pathology analytics technologies. The collaboration aimed to accelerate preclinical pathology workflows and strengthen data-driven drug development capabilities, highlighting the growing integration of artificial intelligence within pharmaceutical research.
Industry Impact & Future Outlook
The next decade is expected to witness a transformative evolution in cardiac safety screening, driven by advancements in automation, artificial intelligence, stem-cell-derived cardiac models, and high-throughput electrophysiology technologies. As pharmaceutical pipelines become increasingly complex and regulatory scrutiny intensifies, HERG screening will remain a foundational requirement for assessing cardiovascular risk.
Market participants that invest in scalable screening platforms, predictive toxicology solutions, and strategic partnerships will be best positioned to capitalize on emerging opportunities across both developed and developing markets. With expanding applications across antiarrhythmic, antipsychotic, antibiotic, and other therapeutic categories, the HERG screening market is poised to play a central role in ensuring safer and more effective drug development worldwide.
Click to Download and Read the Full Report: https://straitsresearch.com/report/herg-screening-market
About Straits Research
Straits Research is a leading global market research and consulting firm dedicated to delivering actionable insights, data-driven intelligence, and strategic business solutions across diverse industries. The company specializes in comprehensive market analysis, competitive intelligence, forecasting, and industry trend assessment, helping organizations make informed decisions in rapidly evolving markets.
